A monoclonal antibody (mAb) that inhibits the proteolytic enzyme, human kallikrein 7, responsible for skin desquamation and central in the development of Atopic Dermatitis. The mAb has granted patent in the USA ( Patent No.: US 12,590,170 B2
Date: Mar. 31, 2026, Puzer et al.